

November 10, 2022

Listing Department **BSE LIMITED** P J Towers, Dalal Street, Fort, <u>Mumbai–400 001</u> Code: 531 335

Listing Department **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), <u>Mumbai–400 051</u> Code: ZYDUSWELL

Sub: Outcome of Board Meeting

Dear Sir / Madam,

The Board of Directors at their meeting held today i.e. November 10, 2022, based on the recommendations of Audit Committee, approved the unaudited financial results for the quarter and half year ended on September 30, 2022.

In this regard, please find enclosed the following:

- the unaudited financial results (standalone and consolidated) for the quarter and half year ended on September 30, 2022, reviewed by the Audit Committee and taken on record by the Board of Directors, today i.e. November 10, 2022 pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations").
- 2. the Limited Review Reports of M/s. Mukesh M. Shah & Co., Chartered Accountants and the Statutory Auditors of the Company certifying the limited review of the unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30, 2022 pursuant to regulation 33 of the Listing Regulations.
- 3. a copy of press release proposed to be published in the newspapers in the matter of unaudited financial results for the quarter and half year ended on September 30, 2022.
 - The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed for trading till November 13, 2022 and shall reopen on and from November 14, 2022 for the Directors and Designated Persons.

Zydus Wellness Limited

(a subsidiary of Zydus Lifesciences Limited) **Regd. Office:** 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India. **Phone No.**: +91-79-71800000; **Website**: <u>www.zyduswellness.com</u> **CIN**: L15201GJ1994PLC023490



The Board meeting commenced at 11:00 a.m. and concluded at 12:10 p.m.

Please find the same in order.

Thanking you,

Yours faithfully, For, **ZYDUS WELLNESS LIMITED**

NANDISH P. JOSHI COMPANY SECRETARY

Encl.: As above

Zydus Wellness Limited

(a subsidiary of Zydus Lifesciences Limited) **Regd. Office:** 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India. **Phone No.**: +91-79-71800000; **Website**: <u>www.zyduswellness.com</u> **CIN**: L15201GJ1994PLC023490

Zydus Wellness			Registered office	e : Zydus Corpor			Zydus Wellness Limited Survey No. 536 Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej		ghway, Ahmeda	bad 382 481.			
vveimess				Chaham			4 0000 Website : www.zyduswellness.com, CIN No : L15201GJ1994Pl ancial Results for the Quarter and Half Year Ended Sep		0000				
		7 in I	akhs	Statem	ent of Unau	aneu rii	lancial Results for the Quarter and Hall fear chued Se	Stember 30, A	022	₹inl	akhe		
₹ in Lakhs CONSOLIDATED								₹ in Lakhs COMPANY					
Quarter Ended Half Year Ended Year Ended						E		Ouarter Ended			Half Year Ended Year Ended		
						Sr. No.	Particulars			Cantanhan	September		March
September	June	September	September	September	March	5-62-0942-30302-P		September	June 30, 2022	September 30, 2021	30, 2022	September 30, 2021	31, 2022
30, 2022	30, 2022	30, 2021	30, 2022	30, 2021	31, 2022			30, 2022	30, 2022		30, 2022	30, 2021	
		[Unaudited]			[Audited]					[Unaudited]			[Audited]
						1	Income						
43 677	60.000	20.012	1 11 075	96,834	1,98,846	a	Revenue from operations Sales	5,920	5,398	4,704	11,318	7,452	19,042
42,677	69,298 378	38,013 352	1,11,975 648	1,289	2,064	1	Other operating income	802	782	534	1,584	1,044	2,583
270	69,676	38,365	1,12,623	98,123	2,004	4 4	Total Revenue from operations	6,722	6,180	5,238	12,902	8,496	21,625
135	195	336	330	575	1,040	ь	Other income	289	371	393	660	815	1,540
43,082	69,871	38,701	1,12,953	98,698	2,01,950	1 5	Total Income	7,011	6,551	5,631	13,562	9,311	23,165
43,002	05,071	30,701	1,12,555	50,050	2,01,930	2	Expenses	7,011	0,551	5,051	10,002	5,511	23,103
20,916	25,012	18,229	45,928	33,188	88,494	a	Cost of materials consumed	4,320	4,151	4,095	8,471	6,457	14,589
1,376	3,254	993	4,630	4,053	9,463	b		, 4/520	-	-	-	-	-
1,570	5,254	555	4,000	1,000	5,105		Changes in inventories of finished goods, work-in-progress	22	2.0				
2,057	3,595	646	5,652	9,281	80		and stock-in-trade	139	83	(206)	222	(5)	654
4,363	4,509	4,230	8,872	8,529	16,356	d		806	746	914	1,552	1,732	3,106
294	414	669	708	1,311	2,551	e		1	45	50	46	99	202
643	604	611	1,247	1,170	2,362	f	Depreciation and amortisation expense	106	72	69	178	137	284
5,169	9,617	4,749	14,786	11,674	23,475	g		-		319	-	429	1,093
7,440	8,877	6,464	16,317	14,302	28,567	h	Other expenses	208	659	592	867	1,789	2,715
42,258	55,882	36,591	98,140	83,508	1,71,348		Total expenses	5,580	5,756	5,833	11,336	10,638	22,643
824	13,989	2,110	14,813	15,190	30,602	3	Profit/ [Loss] before exceptional items and tax [1-2]	1,431	795	(202)	2,226	(1,327)	522
-	291	-	291	•	-	4	Exceptional items [Refer Note 4]	-	•	-		-	
824	13,698	2,110	14,522	15,190	30,602	5	Profit/ [Loss] before tax [3-4]	1,431	795	(202)	2,226	(1,327)	522
						6	Tax expense						
-	-	5.0	-	-		a					-		-
(23)	(3)	(37)	(26)	(37)	(285)	D	Deferred tax	(47)			(47)		(748)
(23)	(3)	(37)	(26)	(37)	(285)	1	Total tax expenses	(47)	- 795	(202)	(47)	(1,327)	
847	13,701	2,147	14,548	15,227	30,887	7	Net Profit/ [Loss] [5-6] Other Comprehensive Income [OCI]	1,478	795	(202)	2,273	(1,327)	1,270
00000	1.1.1	1000	101250	10.000		150 m		(74)		(27)	(77)	(22)	
(17)	(25)	(301)	(42)	(252)	(101)	a		(74)	1	(27)	(73)	(23)	1
8	20	(1)	28	(245)	20	D	Items that will be reclassified to profit or loss [net of tax] Total Other Comprehensive Income [net of tax]	(74)	- 1	(27)	(73)	(23)	1
(9)	(5)	(302)	(14)	14,982	(81) 30,806	9	Total Comprehensive Income [7+8]	1,404	796	(229)	2,200	(1,350)	
838	13,696	1,045	14,554	14,902	30,000	10	Total Comprehensive Income attributable to:	1,404	750	(223)	2,200	(1,550)	1,2/1
838	13,696	1,845	14,534	14,982	30,806	a		1,404	796	(229)	2,200	(1,350)	1,271
6,363	6,363	6,363	6,363	6,363	6,363	11	Paid-up equity share capital [Face Value ₹ 10 each]	6,363	6,363	6,363	6,363	6,363	6,363
0,303	0,505	0,505	0,505	0,505	4,78,040	12	Reserve excluding Revaluation Reserve	0,000	0,000	0,000	-/		3,93,655
				1	1,70,010	13	Earnings per share [EPS]						
						13	[EPS for guarter and half year ended is not annualised]		2				
1.33	21.53	3.37	22.86	23.93	48.54	a		2.32	1.25	(0.32)	3.57	(2.09)	2.00
1.33	21.99	3.37	23.32	23.93	48.54	b		2.32	1.25	(0.32)	3.57	(2.09)	2.00
1.33	21.53	3.37	22.86	23.93	48.54	c		2.32	1.25	(0.32)	3.57	(2.09)	2.00
1.33	21.99	3.37	23.32	23.93	48.54	d	Diluted [₹] - Before exceptional items	2.32	1.25	(0.32)	3.57	(2.09)	2.00
1.33	61.77	5.57	LOIDE		10101				100 100 100	- to make			

Notes :

1 The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on November 10, 2022.

2 The Company operates in one segment, namely "Consumer Products".

3 Due to seasonality of some of the Company's products, Company's Revenues and Profits are skewed in favour of the first and last quarters of the financial year. Hence the performance of these quarters is not representative and cannot be generalised for other quarters.

4 As a part of manufacturing and supply chain network optimisation and to make manufacturing operations leaner and agile to the consumer needs, the Company (and its subsidiaries) has conducted a strategic review of its manufacturing footprint. In view of the same, the Board of Directors of Zydus Wellness Product Limited, a wholly owned subsidiary Company, at their meeting held on June 17, 2022, passed a resolution to cease the operations of Sitarganj manufacturing facility. The Company does not anticipate any material effect due to this decision and the expenses incurred so far in connection with the cessation of Sitarganj facility have been classified as Exceptional items in the above results.

5 Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

₹inL	-212.411.025		₹inL	
CONSOL			COMP	1010000000
As		Particulars	As	
September	March		September	March
30, 2022	31, 2022		30, 2022	31, 2022
[Unaudited]	[Audited]		[Unaudited]	[Audited]
		ASSETS:		
		Non-current assets:		
24,592	24,447	Property, plant and equipment	2,110	2,200
2,123	1,192	Capital work-in-progress	436	17
3,92,002	3,92,002	Goodwill	2,282	2,282
54,373	54,545	Other intangible assets	15	11
		Financial assets:		
-	2	Investments	3,67,125	3,67,12
	1	Loans	13,700	21,69
441	426	Other financial assets	48	4
13,006	12,981	Deferred tax asset [net]	2,793	2,74
1,305	1,701	Other non-current assets	65	7
822	554	Assets for tax [net]	737	51
4,88,664	4,87,848	Total Non Current Assets	3,89,311	3,96,87
31,570	26 164	Current assets: Inventories	766	90
31,570	36,164	Financial assets:	/00	90
	2,702	Investment		1,20
9,879	14,232	Trade receivables	2,984	1,20
8,287	11,538	Cash and cash equivalents	6,181	310
124	5,442	Bank balance other than cash and cash equivalents	57	5,42
	5,112	Loans	203	5,42
2,244	2,101	Other current financial assets	924	73
9,657	9,191	Other current assets	2,437	2,50
61,761	81,370	Total Current Assets	13,552	12,17
5,50,425		Total Assets	4,02,863	4,09,05
0,00,120	5/05/1220	EQUITY AND LIABILITIES:	4,02,005	1,05,05
		Equity:		
6,363	6,363	Equity share capital	6,363	6,36
4,89,392	4,78,040	Other equity	3,92,673	3,93,65
4,95,755	4,84,403	Total Equity	3,99,036	4,00,01
		Liabilities:		
		Non-current liabilities:		
		Financial liabilities:		
	6,250	Borrowings		~
410	471	Lease liabilities	22	3
117	101	Other financial liabilities	99	8
1,338	1,281	Provisions	290	17
	31	Other non-current liabilities	-	
1,865	8,134		411	28
		Current liabilities:		
21.050	31.000	Financial liabilities:		4.00
21,050	31,900	Borrowings	-	4,60
119	113	Lease liabilities	18	1
444	1 744	Trade payables:		
1.191.191.191.191.191.191.191.191.191.1	1,711	Due to micro and small enterprises	25	2
25,063	34,717	Due to other than micro and small enterprises	2,538	3,09
2,601	2,609	Other financial liabilities	614	59
1,332	3,446	Other current liabilities	117	35
2,196	2,185	Provisions	104	6
52,805	76,681		3,416	8,74
5,50,425	5.69.218	Total Equity & Liabilities	4,02,863	4.09.05

₹ in Lal	khs		₹ in Lakhs		
CONSOLID	DATED		COMP	PANY	
Half Year		Particulars	Half Yea		
		Particulars			
September 30, 2022	30, 2021		September 30, 2022	Septembe 30, 2021	
[Unaudi	ted]		[Unau	lited]	
		A. Cash flow from operating activities:			
14,522	15,190	Profit/[Loss] before tax	2,226	(1,32	
		Adjustments for:			
1,247	1,170	Depreciation and amortisation expense	178	13	
9	4	Net loss on disposal of Property, plant and equipment	2		
-	23	Expected credit loss on trade receivables [net]	-		
(220)	(486)	Interest income	(647)	(81	
(110)	(89)	Net gain on investments measured at fair value through statement of profit and loss	(13)		
708	1,311	Interest expense, bank commission and charges	46	9	
(34)	(34)	Amortisation of deferred revenue on Government grants	-	-	
26	376	Provision for employee benefits	94	13	
-	-	Provisions for probable product expiry claims and return of goods	(8)		
16,148	17,465	Operating profit/ [loss] before working capital changes Adjustments for:	1,878	(1,77	
3,748	230	[Increase]/ Decrease in trade receivables	(2,013)	(39	
(54)	907	[Increase]/ Decrease in other assets	100	(21	
4,594	10,840	[Increase]/ Decrease in inventories	139	(2	
(1,395)	(1,398)	[Decrease]/ Increase in other liabilities	(57)	6	
(11,569)	(13,328)	[Decrease]/ Increase in trade payables	(602)	(3	
11,472	14,716	Cash generated from/ [used in] operations	(555)	(2,37	
(267)	(169)	Direct taxes paid [net of refunds]	(223)	(13	
11,205	14,547	Net cash from/[used in] operating activities	(778)	(2,50	
		B. Cash flows from investing activities:			
(1,672)	(4,405)	Purchase of property, plant and equipment and other intangibles assets (including capital work-in-progress and capital advances paid)	(345)	(10	
8	61	Proceeds from sale of Property, plant and equipment	6		
-	-	Repayment of loan by subsidiaries	7,800	4,45	
-	÷	Loan given to subsidiaries	-	(29	
110	89	Net gain from sale of current investments	13		
6	544	Proceeds from/ [Investment in] non-current fixed deposit [net]	-		
220	486	Interest received	456	42	
(1,328)	(3,225)	Net cash from/[used in] investing activities	7,930	4,47	
		C. Cash flows from financing activities:			
(17,100)	(1,598)		(4,600)	1,20	
(84)	(23)		(11)		
(780)	(2,007)		(56)	(8	
(3,184)	(3,187)		(3,184)	(3,18	
(21,148)		Net cash used in financing activities	(7,851)	(2,07	
(11,271)		Net increase/ [decrease] in cash and cash equivalents	(699)	(11	
19,682		Cash and cash equivalents at the beginning of the year *	6,937	8,40	
8,411		Cash and cash equivalents at the end of the year *	6,238	8,40	
		cludes Bank balance other than cash and cash equivalents and Investments in liquid mutua		0,25	

9.1

Place: Ahmedabad Date: November 10, 2022

By Order of the Board, For Zydus Wellness Limited,

.

Dr. Sharvil P. Patel

•

Chairman DIN: 00131995

à.

MUKESH M. SHAH & CO. CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

To, The Board of Directors, Zydus Wellness Limited

- We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Zydus Wellness Limited ['the Company'], for the quarter and half year ended on September 30, 2022 ['the Statement'] attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
- 2. This statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SH M. SHAH 7, Heritage Chamburs, Nehru Nager, Antmadabad-15 Chamburs, Antmadabad-15

Chartered Accountants Firm Regn. No. 106625W

For Mukesh M. Shah & Co

Mukesh M. Shah Partner Membership No. 030190

Place: Ahmedabad Date: November 10, 2022

UDIN: 22030190BCRQWU7239

+91-79-2647 2000 | contact@mmsco.in | www.mmsco.in

⁷th Floor, Heritage Chambers, Behind Bikanerwala Sweets, Near Azad Society, Nehru Nagar, Ahmedabad-380015

MUKESH M. SHAH & CO.

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

To, The Board of Directors, Zydus Wellness Limited

- We have reviewed the accompanying statement of Consolidated unaudited financial results of Zydus Wellness Limited ['the Parent'] and its subsidiaries [the Parent and its subsidiaries together referred to as 'the Group'] for the quarter and half year ended on September 30, 2022 ['the Statement'] attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
- 2. This statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the financial results of the following entities:
 - a) Parent Company
 - i) Zydus Wellness Limited
 - b) Subsidiary Companies
 - i) Zydus Wellness Products Limited
 - ii) Liva Nutritions Limited
 - iii) Liva Investments Limited
 - iv) Zydus Wellness International DMCC
 - v) Zydus Wellness (BD) Pvt Limited
- 5. Based on our review conducted and procedures performed as stated in Paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, as well as the management review nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in Statement.

+91-79-2647 2000 | contact@mmsco.in | www.mmsco.in

7th Floor, Heritage Chambers, Behind Bikanerwala Sweets, Near Azad Society, Nehru Nagar, Ahmedabad-38001

India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of 4 subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect [the figures reported below are before giving effect to consolidation adjustments] total assets of ₹ 3,80,583 Lakhs as at September 30, 2022, total income of ₹ 42,242 Lakhs and ₹ 1,11,481 Lakhs for the quarter and half year ended September 30, 2022 respectively, total net loss after tax of ₹ 5,968 Lakhs and ₹ 4,243 Lakhs for the quarter and half year ended September 30, 2022 respectively, total net loss after tax of ₹ 5,968 Lakhs and ₹ 4,243 Lakhs for the quarter and half year ended September 30, 2022 respectively, total comprehensive income of ₹ (5,911) Lakhs and ₹ (4,212) Lakhs for the quarter and half year ended September 30, 2022 respectively and net cash outflows of ₹ 10,663 Lakhs for the half year ended September 30, 2022, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated financial results also include the financial information of a subsidiary company included in the consolidated unaudited financial results, whose interim financial information reflect [the figures reported below are before giving effect to consolidation adjustments] total assets of ₹ 1,816 Lakhs as at September 30, 2022, total income of ₹ 1,277 Lakhs and ₹ 2,345 Lakhs for the quarter and half year ended September 30, 2022 respectively, total net Loss after tax of ₹ 180 Lakhs and ₹ 252 Lakhs for the quarter and half year ended September 30, 2022 respectively, total comprehensive income of ₹ (180) Lakhs and ₹ (252) Lakhs for the quarter and half year ended September 30, 2022 respectively and net cash inflows of ₹ 91 Lakhs for the half year ended September 30, 2022, as considered in the Statement. No limited review of these financial information has been carried out by the auditors of the subsidiary; however, according to the information and explanations given to us by the Management, these interim financial results/ information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information as certified by the management.

Place: Ahmedabad Date: November 10, 2022


UDIN: 22030190BCRQ RQ2813

MUKESH M. SHAH & CO. CHARTERED ACCOUNTANTS

> For Mukesh M. Shah & Co Chartered Accountants Firm Regn. No. 106625W

Mukesh M. Shah Partner Membership No. 030190

+91-79-2647 2000 | contact@mmsco.in | www.mmsco.in



Zydus Wellness Ltd, Net Sales up by 12.3%

Ahmedabad, November 10, 2022

For the second quarter ended September 30, 2022, Zydus Wellness Ltd. reported consolidated Net sales of Rs.427 crores, up by 12.3% and consolidated revenue from operations of Rs. 429.5 crores. Earnings before Interest, Depreciation and Tax (EBIDTA) stood at Rs. 16.3 crores and reported Net profit for the quarter stood at Rs.8.5 crores.

With the continued thrust on marketing initiatives, several key brands including Glucon-D, Everyuth, Nycil and Nutralite recorded a strong performance during the quarter.

The Sugarfree brand continued its leadership in its category with a market share of over 95 percent¹. During the quarter Sugar free Green doubled its direct distribution during the quarter on a sequential basis. Glucon-D continued to lead the glucose powder category with a value market share of 60.0%, a growth of 157 basis points over the same period last year². The brand registered a strong double digit sales growth.

Glucon-D bagged the Gold Award for its Mother's Day campaign, #MyEnergyMaaEnergy at the SPOTT Awards by Economic times. During the quarter Complan registered a market share of 4.6% in the Health Food Drink (HFD) category³. Nycil has maintained its number one position with a market share of 35% in the Prickly heat powder category⁴, an increase of 47 basis points over the same period last year.

Everyuth Scrub has maintained its number one position with a market share of 41.8% in the facial scrub category, which is an increase of 269 basis points over the same period last year and Everyuth Peel off has maintained its number one position with a market share of 75.7% in the Peel off category. Everyuth brand now has a market share of 6.5% in the overall facial cleansing segment⁵.

Nutralite brand has registered yet another strong double-digit growth during the quarter gone by. Nutralite DoodhShakti dairy portfolio, which includes butter, spreads and ghee delivered strong performance backed by increased distribution drive, festival specific digital activations and online recipe videos endorsed by celebrity Shilpa Shetty.

###

Sources:

*1- as per MAT September '22 report of IQVIA

*2, 3, 4, 5, 6- as per MAT September 2022 report of Nielsen.

For further information please contact : The Corporate Communications Department Regd.Office: 'ZydusCorporatePark', SchemeNo.63, SurveyNo.536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India. Phone: +91-079-71800000, +91-079-48040000 www.zyduswellness.com CIN: L15201GJ1994PLC023490